日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Combined inhibition of atypical PKC and histone deacetylase 1 is cooperative in basal cell carcinoma treatment

非典型 PKC 与组蛋白去乙酰化酶 1 的联合抑制在基底细胞癌治疗中具有协同作用

Amar N Mirza, Micah A Fry, Nicole M Urman, Scott X Atwood, Jon Roffey, Gregory R Ott, Bin Chen, Alex Lee, Alexander S Brown, Sumaira Z Aasi, Tyler Hollmig, Mark A Ator, Bruce D Dorsey, Bruce R Ruggeri, Craig A Zificsak, Marina Sirota, Jean Y Tang, Atul Butte, Ervin Epstein, Kavita Y Sarin, Anthony E

Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor

拉喹莫德通过激活芳烃受体来抑制实验性自身免疫性脑脊髓炎

Joel Kaye, Victor Piryatinsky, Tal Birnberg, Tal Hingaly, Emanuel Raymond, Rina Kashi, Einat Amit-Romach, Ignacio S Caballero, Fadi Towfic, Mark A Ator, Efrat Rubinstein, Daphna Laifenfeld, Aric Orbach, Doron Shinar, Yael Marantz, Iris Grossman, Volker Knappertz, Michael R Hayden, Ralph Laufer

CEP-32496: a novel orally active BRAF(V600E) inhibitor with selective cellular and in vivo antitumor activity

CEP-32496:一种新型口服 BRAF(V600E)抑制剂,具有选择性细胞和体内抗肿瘤活性

Joyce James, Bruce Ruggeri, Robert C Armstrong, Martin W Rowbottom, Susan Jones-Bolin, Ruwanthi N Gunawardane, Pawel Dobrzanski, Michael F Gardner, Hugh Zhao, Merryl D Cramer, Kathryn Hunter, Ronald R Nepomuceno, Mangeng Cheng, Dana Gitnick, Mehran Yazdanian, Darren E Insko, Mark A Ator, Julius L Ap

A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis

CEP-33779 是一种高选择性口服 Janus 激酶 2 抑制剂,可消除两种类风湿性关节炎小鼠模型中的疾病

Kristine L Stump, Lily D Lu, Pawel Dobrzanski, Cynthia Serdikoff, Diane E Gingrich, Ben J Dugan, Thelma S Angeles, Mark S Albom, Mark A Ator, Bruce D Dorsey, Bruce A Ruggeri, Matthew M Seavey